Close

BIO Statement on House Energy & Commerce Committee 340B Drug Pricing Program Review

Washington, DC (January 10, 2018) – BIO President and CEO Jim Greenwood issued the following statement regarding the review of the 340B drug pricing program released by the House Energy & Commerce Committee today:

Washington, DC (January 10, 2018) – BIO President and CEO Jim Greenwood issued the following statement regarding the review of the 340B drug pricing program released by the House Energy & Commerce Committee today:

“We applaud Chairman Walden and his colleagues on the Energy and Commerce Committee for their attention to the rapidly growing 340B program. The findings of today’s report reinforce the clear conclusion that the 340B program has grown far beyond its original scope, leading to growing problems with accountability and transparency. As the report makes clear, there is currently no requirement in the program for 340B covered entities to pass program savings along to uninsured patients – which many covered entities fail to do, while also failing to account for how program profits are used.”

“We applaud the Committee’s call for increased transparency within the program, as well as their call for Congress to clarify the program’s intent and to reassess program eligibility to ensure that 340B discounts are properly serving patients and Congress’s purposes in establishing the program.”

 

Upcoming BIO Events

BIO One-on-One Partnering™ @ JPM
January 7-11, 2018
San Francisco

BIO Asia International Conference
March 19-20, 2018
Tokyo, Japan

BIO CEO & Investor Conference
February 12-13, 2018
New York, New York

BIO International Convention
June 4-7, 2018
Boston, MA

 

###